In this blog post our CEO offers some opinions on UK Research and Innovation's strategy. This was first published by the BioIndustry Association.
Learn about the culture at bit.bio and how it enabled our manufacturing team to bring in new technology to improve our processes.
In this blog, learn about current challenges of hiPSC-derived cell models, best approach for cell generation & future trends for human cell models.
Our CEO writes about the importance of the synthetic biology industry as part of the UK Life Sciences vision. This was first published by the BioIndustry Association.
The translational medicine team will help bit.bio build out its cell therapy pipeline and strategy.
Read this blog to learn how bit.bio are offering easy access to endless and reliable human cells for research and drug discovery.
Our CEO reflects on a recent UN High-Level Political Forum discussion about industry & academia collaborations to achieve sustainable development goals.
Our CEO explains how our opti-ox technology underpins not only bit.bio but also Meatable - a cultured meat company — and why we need to rethink sustainability.